Oric Pharmaceuticals (ORIC) Q4 2025 earnings summary

Executive summary

• Achieved significant clinical milestones in 2025, including promising Phase 1b data for rinzimetostat in mCRPC and enozertinib in NSCLC, supporting best-in-class efficacy and safety profiles.

• Raised $264 million from healthcare specialist funds, extending cash runway into the second half of 2028, beyond key clinical readouts.

• Entered a clinical trial collaboration with Johnson & Johnson to evaluate enozertinib in combination therapy for NSCLC.

Financial highlights

• Cash, cash equivalents, and investments totaled $392.3 million as of December 31, 2025, with a proforma balance of $412.3 million after additional post-quarter financing.

• R&D expenses for Q4 2025 were $25.9 million, down from $32.0 million in Q4 2024; full-year R&D expenses were $109.8 million, down from $114.1 million year-over-year.

• G&A expenses for Q4 2025 were $8.7 million, up from $7.6 million in Q4 2024; full-year G&A expenses were $33.2 million, up from $28.8 million year-over-year.

• Net loss for Q4 2025 was $30.5 million, compared to $36.3 million in Q4 2024; full-year net loss was $129.1 million, compared to $127.8 million in 2024.

• Net loss per share for 2025 was $1.47, compared to $1.83 in 2024.

Outlook and guidance

• Cash and investments expected to fund operations into the second half of 2028, beyond anticipated Phase 3 readouts.

• Multiple clinical data readouts for rinzimetostat and enozertinib anticipated in 2026, with potential initiation of registrational trials.

• Key milestones include Phase 3 trial initiation for rinzimetostat in mCRPC in 1H 2026 and multiple data updates for enozertinib in 2H 2026.